News | April 01, 2022
Oragnon enters global licencing agreement with Dare Biosciences
An estimated 21 million American women experience BV
An estimated 21 million American women experience BV
The plant is scheduled to come on stream in September 2024
The Cidmus brand shall be affixed on the pharmaceutical composition comprising a combination of Valsartan and Sacubitril (currently under Novartis patent) which is indicated for heart failure patients with reduced ejection fraction
Yashoda Hospitals Hyderabad has earned the distinction of becoming the first to introduce BTVA in India
The mAbxience partnership will enable Cipla to continue its ethos of ensuring equitable access to affordable, life-saving medication
The Drug Registry intends to create a nationally recognized source of information on various systems of medicine in the country
Phablecare closed this acquisition for an undisclosed sum, betting on the start-up's holistic approach to Type 1 Diabetes management
Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets
The registry will be conducted for approximately two and a half years and up to 200 subjects will be enrolled
Approval is based on results of a multicenter, randomized, open-labeled and controlled IDE clinical study that demonstrated the superiority of Agili-C™ implant to the current surgical standard of care, debridement and microfracture in the knee joint
Subscribe To Our Newsletter & Stay Updated
